Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ATPC | Agape Atp | $4.01 | $1.99 | 98.52% | 936K | $2.0M | $1.72$128.25 |
| ACXP | Acurx Pharmaceuticals | $2.74 | $0.79 | 40.15% | 20.6M | $5.0M | $1.33$21.00 |
| INKT | MiNK Therapeutics | $13.66 | $3.21 | 30.72% | 220.2K | $49M | $6.34$76.00 |
| MGNX | MacroGenics | $2.98 | $0.62 | 26.06% | 2.1M | $149M | $0.99$3.00 |
| PIII | P3 Health Partners | $3.62 | $0.74 | 25.50% | 242.7K | $9.5M | $1.52$11.30 |
| TTEC | TTEC Holdings | $3.12 | $0.63 | 25.30% | 40.9K | $121M | $1.98$5.60 |
| LFMD | LifeMD | $3.83 | $0.71 | 22.60% | 3.6M | $150M | $2.56$15.84 |
| AGCC | Agencia Comercial Spirits | $22.10 | $3.90 | 21.43% | 18.5K | $626M | $3.66$24.98 |
| VYGR | Voyager Therapeutics | $4.98 | $0.87 | 21.17% | 57.7K | $229M | $2.65$5.55 |
| ZVRA | Zevra Therapeutics | $10.89 | $1.77 | 19.41% | 166.5K | $513M | $6.19$13.16 |
| IXHL | Incannex Healthcare | $5.04 | $0.81 | 19.15% | 30.6K | $49M | $2.40$49.80 |
| AXTI | AXT | $45.91 | $7.35 | 19.06% | 376K | $2.1B | $1.13$47.03 |
| PLYX | Polaryx Therapeutics | $4.17 | $0.65 | 18.47% | 345.7K | $167M | $2.20$48.91 |
| OCC | Optical Cable | $7.20 | $1.09 | 17.76% | 312.9K | $54M | $2.40$11.50 |
| FGI | Fgi Industries | $4.01 | $0.60 | 17.66% | 6.2K | $6.5M | $2.28$12.62 |
| GEMG | Themes ETF Trust - Leverage Shares 2x Long Gemi Daily ETF | $2.97 | $0.44 | 17.45% | 46.3K | - | $1.13$17.73 |
| TKNO | Alpha Teknova | $2.47 | $0.35 | 16.51% | 7.6K | $114M | $1.91$7.48 |
| TENX | Tenax Therapeutics | $12.83 | $1.81 | 16.43% | 923.8K | $69M | $4.63$18.38 |
| CAPR | Capricor Therapeutics | $35.41 | $4.78 | 15.61% | 86.2K | $1.7B | $4.30$40.37 |
| CRMU | Themes ETF Trust - Leverage Shares 2x Long Crml Daily ETF | $8.69 | $1.09 | 14.37% | 21.3K | - | $6.52$15.25 |
| GITS | Global Interactive Technologies | $2.57 | $0.31 | 13.72% | 75.6K | $8.3M | $0.66$7.09 |
| NUCL | Eagle Nuclear Energy | $6.04 | $0.65 | 12.06% | 190.9K | $53M | $4.55$9.65 |
| UECG | Themes ETF Trust - Leverage Shares 2x Long Uec Daily ETF | $10.05 | $0.97 | 10.69% | 17.4K | - | $7.57$15.46 |
| APPX | Investment Managers Series Trust II - Tradr 2x Long App Daily ETF | $41.51 | -$6.64 | -13.79% | 402.7K | - | $20.21$157.62 |
Related Articles
Featured Article
Here's Why This Biotechnology Skyrocketed by 439% in December
Lee Samaha|Jan 9, 2026
A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an exciting new treatment.
1 Small-Cap Stock I'd Buy Before GLBE in 2026
Marc Guberti|Jan 8, 2026
Global-E Online is a small company trying to carve out a niche in the competitive e-commerce space, while AXT is a small semiconductor player that already has a lead in an emerging opportunity.
2 Biotech Stocks That Could Make You Richer
James Halley|Jul 14, 2023
These biotech companies are seeing a spike in revenue growth.
Pfizer and Novartis Are Betting On This Under-the-Radar Biotech. Should You?
Keith Speights|Mar 19, 2022
Voyager Therapeutics has promising technology. But the stock is very risky.
Parkinson's Disease Patients Get Long-Term Benefits From Experimental Gene Therapy
Cory Renauer|Sep 11, 2020
Three years after treatment with NBIb-1817, Parkinson's disease patients still are still showing improvements.
Is Now a Good Time To Buy Neurocrine Biosciences?
James Halley|May 14, 2020
The biopharmaceutical company has seen shares rise 44.5% in less than two months.
3 Small-Cap Biotech Stocks That Surged Last Week
Cory Renauer|May 11, 2020
Here's what's behind their impressive market performances.
4 Stocks Battling Breast Cancer
David Haen|Oct 26, 2019
With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.
3 Biotechs That Have Doubled This Year (Acquisition Next?)
Brian Orelli, PhD|Jul 2, 2019
Good news has a way of attracting suitors.
3 Cancer Treatment Stocks to Buy Right Now
Keith Speights, Chuck Saletta, and Todd Campbell|May 23, 2019
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.
